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ABSTRACT
Graft-versus-host disease and disease relapse are the 2 major causes of failure of allogeneic hematopoietic stem
cell transplantation (SCT). Ideally, patients who undergo transplantation for malignancies would receive the
minimum effective acute graft-versus-host disease (GVHD) prophylaxis to maximize the graft-versus-tumor
potential of the allogeneic SCT. Tailoring acute GVHD prophylaxis to the risk for each patient has long been
a goal for SCT, but no practical way to adjust acute GVHD prophylaxis has been developed. In murine models
of acute GVHD, gut damage from the preparative regimen resulting in the release of many mediators is crucial
for initiation of acute GVHD. Using diarrhea as a marker of gut damage, we performed a retrospective study
of patients at the Johns Hopkins Hospital given matched sibling transplants for chronic myelogenous leukemia
to determine whether gut damage during the preparative regimen is predictive of the development of acute
GVHD in humans. Logistic regression models were used to perform the retrospective analysis of the relation
of diarrhea during the preparative regimen to a significant acute GVHD grade. This work demonstrated a
significant positive correlation between the sum of diarrhea on days 4 to 7 after SCT and acute GVHD and
showed a borderline significant positive correlation between the sum of diarrhea on days 1 to 3 and acute
GVHD. This is the first correlation demonstrated between gut damage during the preparative regimen and
acute GVHD severity in humans. This suggests that damage from the preparative regimen could be used as a
marker for the risk of acute GVHD. Prospective trials would have to test whether acute GVHD prophylaxis
could be adjusted according to this risk. This may result in a greater graft-versus-tumor effect for patients with
less risk of acute GVHD.
© 2005 American Society for Blood and Marrow Transplantation
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RNTRODUCTION
Acute graft-versus-host disease (GVHD) remains
ne of the major causes of treatment failure after stem
ell transplantation (SCT). Relapse of the underlying
alignancy is the other main reason that allogeneic
ransplantations are not successful. Although a graft-
ersus-tumor (GVT) effect seems to be associatedo. G. and D. A. J. contributed equally to this article.
B &MTith GVHD in certain diseases [1], balancing the risk
f acute GVHD with maximizing the GVT response
as proven to be difﬁcult on an individual patient
asis. Although many factors have been associated
ith greater risks of acute GVHD, these factors often
re statistical associations that are usual in selecting
mong potential donors but are often too weak an
ssociation to be applicable at a single patient level.
isk factors include older age of the donor, older age
f the recipient, HLA-mismatched donor, matched
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1nrelated donor, minor histocompatibility antigen
ismatches, and an alloimmunized female donor in a
ale recipient. Several investigational laboratory tests
ave been developed that individualize the risk of
cute GVHD, such as interleukin (IL)–10 promoter
olymorphisms [2], but these research tests are costly
nd not widely available. Patients and donors are often
nable to wait on the outcome of these tests because of
enuous remissions and the ﬁnancial burden of waiting
t the transplant center while the tests are performed.
Thus, a simple indicator of acute GVHD risk is
xtremely desirable. For patients at high risk of acute
VHD, prophylaxis could be augmented. Patients at
ow risk of acute GVHD with a high risk of relapse
ould have acute GVHD prophylaxis more rapidly
apered or could have the intensity decreased. We
ostulate that events early in the induction of acute
VHD may be predictive on an individual basis of the
evelopment of acute GVHD. In acute GVHD in-
uction, the preparative regimen (irradiation, chemo-
herapy, or both) causes damage to the host tissue
hrough local release of tumor necrosis factor
TNF)–, IL-1, and other cytokines [3]. These cyto-
ines cause host tissue damage, increase the expression
f major histocompatibility complex and minor anti-
ens, and activate donor T cells. In response, the
onor T cells secrete T-helper type 1 cytokines such
s IL-2 and interferon , which prime macrophages to
roduce systemic TNF- and IL-1 when triggered by
ipopolysaccharide (LPS) [4]. The cytotoxic T cells
nd other effectors cause further tissue damage and
he clinical manifestations of acute GVHD [3,5,6].
This acute GVHD model implies that damage to
he gastrointestinal (GI) tract during conditioning is a
ey step in propagation of acute GVHD through a
ositive-feedback mechanism. The source of the sys-
emic LPS triggering macrophages has been proposed
o be translocation to the systemic circulation from
he gut after conditioning-induced damage to the mu-
osa [7,8]. This model of acute GVHD is supported
y evidence that shows a decreased risk of acute
VHD if gut decontamination is performed before
ransplantation [9,10]. Also, increased intestinal dam-
ge and acute GVHD severity have been correlated in
ice with donor sensitivity to LPS [11]. Therefore, if
he integrity of the gut is disrupted during the pre-
arative regimen, LPS is released into the serum, and
his results in more release of IL-1 and TNF-.
hrough the different mechanisms discussed previ-
usly, these cytokines further damage the gut, ulti-
ately causing more cytokine release and more tissue
amage. This mechanism implies that increased gut
amage during the preparative regimen should corre-
ate with an increased risk of clinical acute GVHD.
lthough this correlation has been demonstrated in
urine systems, it has not been demonstrated in hu-
ans. v
02If a relationship were found between gut damage
uring the conditioning regimen of SCT and acute
VHD, this would be a very direct and simple way to
ustomize acute GVHD prophylaxis. Patients with
igniﬁcant GI toxicity might then beneﬁt from an
ugmented acute GVHD prophylaxis strategy,
hereas patients without toxicity could receive stan-
ard or even reduced prophylaxis, especially if they
ave malignancy at high risk of relapse, to maximize
he GVT effect.
Because a damaged mucosa is deﬁcient at absorb-
ng both water and ions, it is reasonable to expect that
iarrhea is an easy and accurate method of measuring
I toxicity, even though no previous human studies
ave formally linked diarrhea with gut toxicity or
ytokine increases during preparative regimens of
CT. If this toxicity is important in the generation of
cute GVHD, then the amount of diarrhea would be
redictive of the severity of acute GVHD. Other po-
ential markers, such as cytokine levels, are expensive
nd labor intensive and require time to measure. More
mportantly, the peak cytokine level may be missed
nd is likely to occur locally at the site of injury.
andom blood levels are not necessarily reﬂective of
hat is happening to the GI tissue. Therefore, we
erformed a retrospective study to determine whether
he quantity of diarrhea temporally related to the
reparative regimen correlates with the development
f acute GVHD. Most patients receiving allogeneic
ransplantations with a full myeloablative preparative
egimen have received intensive prior chemotherapy.
he chemotherapy and prior infections may have al-
eady damaged end organs such as the liver and gut.
o minimize this potential confounding effect, we
xamined chronic myelogenous leukemia (CML) in
hronic phase—this group of patients has had minimal
oxic therapy before transplantation.
ATIENTS AND METHODS
atients and Data
Two hundred twenty-eight patients receiving al-
ogeneic transplants for CML from matched sibling
onors with either unmanipulated or elutriated [12]
rafts between 1981 and 2001 were included in this
tudy. Elutriation was used from 1988 on in several
ifferent protocols. These patients were identiﬁed
hrough a computerized database of patients who un-
erwent transplantation at Johns Hopkins Hospital.
he characteristics of this patient population are dem-
nstrated in Table 1. Preparative therapy consisted of
ither busulfan (1 mg/kg every 6 hours for 16 doses)
ollowed by cyclophosphamide (50 mg/kg/d for
days) or cyclophosphamide followed by total body
rradiation (3 Gy daily for 4 days). GVHD prophylaxis
aried and depended on institutional trials at a partic-
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Gastrointestinal Toxicity and the Risk of GVHD
Blar time. Most patients received cyclosporine alone
r cyclosporine with another agent (methotrexate,
ethylprednisolone, or thalidomide). Table 1 in-
ludes details on GVHD prophylaxis. Patients did not
eceive antibiotics for GI decontamination before
ransplantation. They did not receive cytokine sup-
ort after their transplantation. All patients received
rophylactic antibacterial, antiviral, and antifungal an-
ibiotics after transplantation. Furthermore, they re-
eived a variety of empiric antibiotics for fevers. Stan-
ards on empiric antibiotics used for ﬁrst fevers
hanged over the long time course that this study
overs.
All patients had surveillance stool cultures (for
iruses, resistant bacteria, and fungi) sent until 1998,
hen the practice of surveillance cultures was discon-
inued. During the entire study period, patients who
ad diarrhea 500 mL in 24 hours were evaluated
ith at least 2 sets of stool cultures. Patients were not
onsidered for symptomatic therapy for diarrhea until
he results of 2 negative sets of stool cultures obtained
4 hours apart were reviewed. GVHD staging was
erformed weekly by a dedicated GVHD team. The
aximum grade of acute GVHD was also recorded by
sing the Keystone criteria [13], which are based on
etermined stages of skin, gut, and liver acute GVHD.
summary of the distribution of these stages is pre-
ented in Table 2. Patients were assigned as either
aving signiﬁcant acute GVHD (grade II-IV) or not
able 1. Demographics of Patients
Variable Data
o. patients 228
ex (M/F) 145/83
ge (y)
Mean 36
Range 4-60
reparative regimen
Busulfan-based 71
TBI-based 157
lutriation 49
VHD prophylaxis
Cyclophosphamide 4
CSA alone 128
CSA with other agents* 87
MTX alone 1
None 8
BI indicates total body irradiation; CSA, cyclosporine; MTX,
methotrexate.
All in combination with MTX except in 20 patients who were part
of a CSA/thalidomide prophylaxis trial.
able 2. Breakdown of Skin, Gut, and Liver Acute GVHD
Organ Stage 0 Stage 1
Skin 43 45
Gut 121 61
Liver 108 30
B&MTaving signiﬁcant GVHD (none or grade I). Diagno-
is of acute GVHD at our center is made with both
linical and histologic information.
tatistical Analysis
The major statistical aim of this study was to
dentify factors associated with grade II to IV acute
VHD after bone marrow transplantation through
ay 100. These factors were selected on the basis of
ross tabulations and logistic regression modeling.
ross tabulations were analyzed with 2 or Fisher’s
xact tests where appropriate. Logistic regression
odels [14] were used to determine the effects of
ultiple factors on these outcomes. Factors of interest
ncluded age, sex, diarrhea, bacterial culture, fungal
ulture, viral assay, parasite assay, T-cell depletion,
arrow depletion, and several GVHD drugs.
The repeated measurements for stool data were
aken on the 8 days before SCT, the day of SCT, and
he 7 days after SCT. Missing data points (1.0%)
ere imputed very simply as the average of the days
efore and after the missing value. Both the sum of
iarrhea during this period and the sum of diarrhea
uring 5 equivalent subdivisions of the period (four
-day periods and a 4-day period) were recorded. To
revent bias, the time divisions, which are arbitrary,
ere agreed on before the retrospective data review
as conducted. Speciﬁcally, we grouped our data into
pretransplantation group and a posttransplantation
roup and then subdivided those groups into approx-
mately equal groups in a random fashion. All P values
re 2 sided. Computations were performed with SAS
SAS Institute, Cary, NC) [15] or EGRET (Statistics
nd Epidemiology Research Corp., Seattle, WA) [16].
ESULTS
Of the 35 patients who had 1 L of diarrhea, 23
atients (66%) developed signiﬁcant acute GVHD. Of
he 193 patients with 1 L of diarrhea during the
tudy period, 144 (75%) developed acute GVHD.
ividing the 16-day period into four 3-day periods
nd one 4-day period revealed a positive correlation
etween the diarrhea volume in 1000-mL increments
n days 4 through 7 and the severity of acute
VHD seen later as a result of transplantation. For
his period, the odds ratio was 1.50, with a P value of
04. Also, the volume of diarrhea from day1 through
ay 3 correlated with acute GVHD severity, with
Stage 2 Stage 3 Stage 4
77 55 8
20 11 15
47 16 27
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1orderline signiﬁcance. The odds ratio was 1.45 (95%
onﬁdence interval, 0.94-2.22), with a P value of .09.
here was no correlation between volumes of diarrhea
uring the time periods before stem cell infusion.
etails of this analysis are included in Table 3. The
um of the total diarrhea volume from day 8 to day
7 also did not correlate with an odds ratio for grade
I to IV acute GVHD of 1.01 (P  .13). The reported
ffect for diarrhea remained signiﬁcant when adjusted
or other factors associated with acute GVHD (Table
). The multivariate regression for our data demon-
trated a disproportionately large number of patients
ith severe acute GVHD who had positive fungal
ultures. There was a disproportionately small num-
er of patients with severe acute GVHD whose SCT
as elutriated and who had positive stool cultures for
acteria. Finally, in Table 5 we show mean stool
utput pertime period, comparing patients with
VHD to those without. Of note, during the day
4-7 time period, patients with eventual grade
I-IV acute GVHD had a mean output of 637 mL.
ISCUSSION
This study investigated whether diarrhea during
he preparative regimen is correlated with the risk of
cute GVHD. The implication of a positive correla-
ion would be extremely provocative, because it would
uggest that this simple measure could be used to
ailor GVHD prophylaxis in each patient. A positive
able 3. Univariate Logistic Regression for Odds of Acute GVHD Gra
Variable
um of diarrhea volume for days 8 to 7*
um of diarrhea volume for days 8 to 6*
um of diarrhea volume for days 5 to 3*
um of diarrhea volume for days 3 to 0*
um of diarrhea volume for days 1 to 3*
um of diarrhea volume for days 4 to 7*
-y age increase
ale sex
ositive bacterial stool culture during preparative regimen
ositive fungal stool culture during preparative regimen
ositive viral stool culture during preparative regimen
lutriation
VHD prophylaxis—CSA alone versus CSA with other agents
SA indicates cyclosporine.
Odds ratios were calculated for 1000-mL increments of diarrhea a
able 4. Multivariate Logistic Regression for Odds of Acute GVHD G
Variable
ositive bacterial culture during preparative regimen
ositive fungal culture during preparative regimen
lutriation
VHD prophylaxis—CSA alone versus CSA with other agents
um of diarrhea volume for days 4 to 7SA indicates cyclosporine.
04orrelation was found. In mice, TNF- production in
esponse to systemic LPS translocated from the gut is
mportant in the initiation of acute GVHD. Direct
ntagonism of LPS in the mouse model reduced se-
um TNF- levels, decreased intestinal pathology,
mproved survival, and reduced clinical acute GVHD
17]. Mice that received LPS-resistant bone marrow
ransplants were demonstrated to develop signiﬁcantly
ess acute GVHD, as measured by mortality from
cute GVHD and clinical score based on weight loss,
osture, activity, fur texture, and skin integrity [11].
linically, diarrhea during and after the preparative
egimen should be reﬂective of gut toxicity. There-
ore, the correlation between gut damage in patients
measured by diarrhea volume) and acute GVHD pro-
ides support that this model of acute GVHD induc-
ion is valid in patients receiving myeloablative trans-
lants.
This study is not the ﬁrst to suggest that the
urine model of gut primacy may have implications
or the medical management of patients receiving
CT. Two studies evaluating gut decontamination
evealed a signiﬁcant decrease in acute GVHD mor-
ality and severity [9,10]. In a retrospective trial,
eelen et al. [10] analyzed the inﬂuence of intestinal
acterial decontamination on the occurrence of grade
I to IV acute GVHD. All patients received strict
rotective isolation and intestinal antimicrobial de-
ontamination. Twenty-three percent of patients de-
eloped severe acute GVHD. In these patients, there
IV
Odds Ratio 95% Confidence Limits P value
1.01 1.00-1.02 .13
1.04 0.66-1.62 .88
1.03 0.68-1.57 .89
1.12 0.78-1.61 .55
1.45 0.94-2.22 .09
1.50 1.03-2.18 .04
0.99 0.97-1.02 .86
1.26 0.69-2.29 .45
0.42 0.22-0.80 .01
2.45 1.35-4.44 .003
0.37 0.02-6.01 .48
0.25 0.13-0.49 <.0001
0.25 0.12-0.51 .0002
continuous variables.
to IV
Odds Ratio 95% Confidence Limits P value
0.36 0.17-0.77 .01
3.25 1.59-6.61 .001
0.39 0.18-0.88 .02
0.24 0.10-0.57 .001
2.01 1.20-3.37 .01de II torade II
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Bas a signiﬁcant correlation with unsuccessful sup-
ression of gut ﬂora. Successful growth suppression of
naerobic bacteria speciﬁcally was associated with a
igniﬁcant reduction in incidence of acute GVHD.
Also, increased TNF- levels in the serum of
atients during conditioning have been correlated
ith the development of acute GVHD. Holler et al.
6] demonstrated in a retrospective study that in-
reased TNF- levels between days 8 and 100
orrelated with major transplant-related complica-
ions. In the cohort of patients with no major compli-
ations, TNF- levels increased to a maximum of 76 	
9 pg/mL. However, the patients with major compli-
ations showed mean increases of 492 	 235 pg/mL
P  .0001). Remberger et al. [18] built on Holler’s
ork to demonstrate the relationship between TNF
evels during conditioning and acute GVHD. In this
tudy, high TNF- levels measured once between
ays 6 and 1 were the only statistically signiﬁcant
isk factor for acute GVHD. Patients who developed
rade II to IV acute GVHD had mean levels of
60 pg/mL, compared with 443 pg/mL for control
atients (P  .001). This correlation was not depen-
ent on the conditioning regimen. Finally, recent
ork by Fowler et al. [19] further supports this rela-
ionship between TNF- and acute GVHD. Through
onocyte intracellular ﬂow cytometry, this group
emonstrated that an increase of monocyte TNF-
fter nonmyeloablative transplantation correlated
ith increased gut acute GVHD severity.
The role of TNF has also been demonstrated by
se of monoclonal antibodies against TNF- to treat
cute GVHD. Herve et al. [20] applied this antibody
or the treatment of refractory severe acute GVHD.
ourteen of 19 patients demonstrated at least a partial
esponse, although disease recurred in all but 2 of
hese patients upon discontinuation of the drug.
oller et al. [3] have also used an anti-TNF antibody
s prophylaxis against acute GVHD during the con-
itioning regimen. Prophylactic blockage of TNF-
pparently postponed the onset of acute GVHD from
ay 15 to day 25 (P  .05) after SCT after cyclophos-
hamide/total body irradiation and from day 33 to day
3 after SCT after busulfan/cyclophosphamide. The
able 5. Summary of Data
Variable
ositive fungal culture
ositive bacterial culture
mount of stool in time period, mL, mean (95% CI)
Day 8 to 6
Day 5 to 3
Day 2 to 0
Day 1 to 3
Day 4 to 7ailure of this approach to totally prevent acute a
B&MTVHD is not surprising in that there are many re-
undant pathways for acute GVHD induction. The
ffects of TNF blockade are not complete with respect
o the prevention of acute GVHD. Also, TNF block-
de is risky, because it may decrease the GVT effect in
ddition to the GVHD effect. This decrease has been
emonstrated in murine systems. Murine recipients of
NF- p55 receptor-deﬁcient T cells demonstrated a
ecrease in donor cytotoxic lymphocyte activity after
one marrow transplantation and, consequently, an
ncrease in the rate of leukemic relapse [21].
This study directly linked gut toxicity, as mani-
ested by diarrhea, after the conditioning regimen to
he development of severe acute GVHD. As reviewed
y Hill and Ferrara [8], GI toxicity, with GI damage
eading to LPS and TNF- production during the
reparative regimen, is well established. Likewise,
NF- production leading to diarrhea is an indisput-
ble fact and is the cornerstone of therapy for patients
ith inﬂammatory bowel diseases, particularly Crohn
isease [22,23], in which diarrhea is the one of the
ajor manifestations of the disease. This work sug-
ests that tailoring prophylactic regimens according to
he gut toxicity from the preparative regimen may
llow individualization of acute GVHD prophylaxis. If
hown to be true, this could provide signiﬁcant beneﬁt
o patients.
From our analysis, the volume of diarrhea after
tem cell infusion is predictive of the severity of acute
VHD from the transplantation. However, because
any patients start showing signs of gut toxicity with
maller volumes of diarrhea ﬁrst, it is likely prudent to
arefully monitor trends of diarrhea from the start of
he preparative regimen. Further studies to prospec-
ively evaluate this observation are warranted.
The magnitude of our odds ratios demonstrates
he complexity of the problem we are faced with. The
elatively low value can be partially explained because
ur analysis was based on continuous variables, and
he odds ratio represents the incremental odds of
cute GVHD with each additional 1000 mL of diar-
hea. However, we cannot ignore the likelihood that
here are other potential predictors of acute GVHD
D Grade 0-I (n  62) GVHD Grade II-IV (n  166)
28 124
23 39
306 (181-431) 321 (211-431)
465 (312-618) 480 (366-594)
778 (565-991) 854 (724-984)
630 (470-789) 836 (703-970)
637 (479-794) 964 (791-1136)GVHfter SCT. For example, minor histocompatibility an-
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1igen mismatch and incidental infections during SCT
ay also be predictive of acute GVHD severity.
There are several areas of potential concern with
his study. First, the study covered a long period of
ime. Changes in the practice of evaluating GVHD
ould have a signiﬁcant effect on the diagnosis of
VHD. However, GVHD staging was performed
eekly by a dedicated GVHD team. Thus, the pa-
ients were seen and staged on the basis of a consistent
valuation. Although members of the group changed
ver time, one of the investigators for this study was
resent through the entire time. Moreover, the diag-
osis of GVHD was always made by biopsy. Gut
VHD was diagnosed on the basis of biopsy evidence
f the lower GI tract (colonoscopy or sigmoidoscopy).
nother potential concern would be that patients who
ave the most severe gut toxicity are unable to absorb
ral prophylactic medications and would, therefore,
e more likely to develop more severe acute GVHD.
owever, acute GVHD prophylaxis was given exclu-
ively parenterally until it was proven (by drug levels)
hat the patient was able to take oral medications.
Another interesting ﬁnding in this study was the
orrelation of positive fungal surveillance stool cul-
ures with the development of acute GVHD. Our
ssumption is that patients with greater mucosal dam-
ge are at greater risk for colonization with fungus. At
his point, it is not known what role the colonization
layed in GVHD. A signiﬁcant GI infection may
ncrease the severity of acute GVHD by increasing the
evels of cytokines both systemically and in the gut.
nfection may generate a positive-feedback loop that
ncreases acute GVHD severity in the same manner as
he preparative regimen. However, colonization is not
vidence of actual tissue infection and damage. The
ositive fungal cultures may be due to changes made
n antibiotic/antifungal prophylaxis (ie, expanding an-
imicrobial coverage) given as a result of the diarrhea.
his interesting and provocative ﬁnding certainly de-
erves further study. However, because of the many
hanges in antibiotic and antifungal prophylaxis and
mpiric therapy during the course of the study, this
uestion can not be adequately addressed from this
ata set.
Also very interesting was the ﬁnding that positive
acterial cultures were associated with a decreased risk
f acute GVHD. Because patients with positive cul-
ures received antibiotics directed at the speciﬁc or-
anism in addition to their empiric antibiotic cover-
ge, their reduced incidence of acute GVHD may be
ue to decreasing gut cytokine production with treat-
ent of the speciﬁc organism. This ﬁnding is consis-
ent with the prior studies that demonstrated a pro-
ective effect from gut decontamination. Again, this
nding can be properly be addressed only in a con-
rolled prospective study.Clearly multiple other factors can be associated
06ith increased acute GVHD, such as increasing age,
emale into male donor, mismatch of minor histocom-
atibility antigens, and subtherapeutic levels of cal-
ineurin inhibitor. In addition, the use of granulocyte
olony-stimulating factor was recently reported to be
ssociated with increased GVHD in patients who re-
eived bone marrow transplants for acute myeloge-
ous leukemia [24]. Although a study of our magni-
ude did not allow us to look at all these factors, the
ope is that future studies will evaluate how the pres-
nce of diarrhea early after hematopoietic SCT may
odulate GVHD in the presence or absence of cer-
ain other risk factors.
The question as to whether increased diarrhea
arly after hematopoietic SCT affects the GVT effect
emains. Although we did not consider relapse in this
rticle, it would be a very interesting topic for a con-
rolled prospective study. Certainly, the need to ade-
uately answer this question further supports the ini-
iation of a prospective study. Because the relapse rate
f CML is very low, it would be difﬁcult to detect a
igniﬁcant GVT effect in a population of patients as
mall as ours. We would more likely see such an effect
n a larger, prospective study.
In conclusion, this study has demonstrated that
ut toxicity secondary to the preparative regimen is
ssociated with an increased risk of acute GVHD.
his ﬁnding implies that measuring the diarrhea vol-
me in the week after stem cell infusion may be a
seful strategy for predicting the severity of acute
VHD and, therefore, may allow tailoring prophy-
axis to the needs of each patient. Future prospective
tudies should look at diarrhea during this time period
nd the relapse rate to understand whether there is an
ssociation between early diarrhea and the GVT ef-
ect.
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